Industry mutes doctors

Share this article:

Drugmakers are paying less to get doctors talking, reports ProPublica, which has found the the industry has slashed the amount of money it spends on speakers' fees.

As examples, the nonprofit notes that Eli Lilly spent 55% less on speakers in 2012 than it did in 2011, Pfizer spent 62% less and Novartis whittled its speaker spend by 40%. In terms of numbers, this comes down to Lilly spending $21.6 million in 2012, compared to $47.9 million three years ago, while Pfizer dropped only $8.3 million on speakers in 2012, compared to $22 million in 2011.

ProPublica notes that not all companies have reduced their spend and that some companies attributed their reduced speakers' budgets to lack of pipeline excitement as opposed to fear of Sunshine Act disclosures.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.